Pfizer lifts annual sales forecast for COVID-19 vaccine
. A man receives a second dose of the Pfizer-BioNTech vaccine against the coronavirus disease (COVID-19) at the hall three of the Belgrade Fair, in Belgrade, Serbia, April 13, 2021. /Marko Djurica Pfizer Inc (NYSE:PFE) on Tuesday raised its annual sales forecast for the COVID-19 vaccine it co-developed with Germany's BioNTech SE (NASDAQ:BNTX), as a vaccination drive across the globe intensifies. The U.S. drugmaker now expects sales of $26 billion from the vaccine in 2021, up from its prior forecast of about $15 billion. The goal assumes that 1.6 billion vaccine doses will be delivered in the year. Cost and gross profit from the vaccine are split 50-50 between Pfizer and BioNTech. Pfizer has said it expects to profit from the vaccine, while some drugmakers including Johnson & Johnson (NYSE:JNJ) have said their vaccine will be available on a not-for-profit basis until the end of the pandemic.